Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) is now available.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has released its unaudited first quarterly report for 2025, covering the period ending March 31, 2025. The report, prepared according to PRC Accounting Standards, was approved by the board of directors, with all directors in attendance. The company emphasizes the accuracy and completeness of the report, reflecting its commitment to transparency and accountability in its financial disclosures.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company, along with its subsidiaries, focuses on the development and production of pharmaceutical products.
YTD Price Performance: 11.11%
Average Trading Volume: 3,890,561
Technical Sentiment Signal: Sell
Current Market Cap: HK$15.5B
For detailed information about 9989 stock, go to TipRanks’ Stock Analysis page.